Welcome to our dedicated page for Churchill Capital X SEC filings (Ticker: CCCXU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Churchill Capital Corp X (CCCXU) provides direct access to the company’s regulatory disclosures as a Nasdaq-listed blank check company. Churchill X files reports with the U.S. Securities and Exchange Commission that describe its SPAC structure, unit composition, governance changes and its proposed business combination with ColdQuanta, Inc. (Infleqtion).
Key documents for CCCXU include Current Reports on Form 8-K that outline material events. For example, a Form 8-K dated July 2, 2025 details the commencement of separate trading for the units, Class A ordinary shares (CCCX) and warrants (CCCXW), including the warrant exercise terms. Another Form 8-K dated September 8, 2025 summarizes the Agreement and Plan of Merger and Reorganization with Infleqtion, the planned domestication from the Cayman Islands to Delaware, the intended name change to "Infleqtion, Inc." and the conditions required to close the Transactions.
Through this page, users can review Churchill X’s registration statement on Form S-4 and related proxy statement/prospectus once filed and declared effective. These filings explain the proposed issuance of securities in the business combination, shareholder voting matters, risk factors and detailed descriptions of Infleqtion’s business. Additional filings may include periodic reports and further 8-Ks documenting board changes, director compensation agreements and other governance matters.
Stock Titan enhances access to these filings with AI-powered tools that summarize lengthy documents, highlight key sections such as transaction structure, closing conditions and dilution mechanics, and help users quickly locate information on unit terms, warrant features and the domestication process. Investors can also use this page to monitor any future Forms 4 or other ownership-related filings that may be associated with Churchill X’s directors, officers or sponsor entities as they are reported to EDGAR in real time.
Infleqtion, Inc. reported that director David B. Singer was granted stock options covering 33,928 shares of common stock at an exercise price of $12.59 per share. The options vest in full on the earlier of May 23, 2027 or the issuer's next annual stockholder meeting after April 10, 2026, subject to his continuous service. These options expire on April 10, 2036. According to the disclosure, the economic benefit of this director compensation passes to Maverick Ventures Investment Fund, L.P. through a management fee offset, and Singer disclaims beneficial ownership except to the extent of his pecuniary interest.
Infleqtion, Inc. reported that director David B. Singer was granted stock options covering 33,928 shares of common stock at an exercise price of $12.59 per share. The options vest in full on the earlier of May 23, 2027 or the issuer's next annual stockholder meeting after April 10, 2026, subject to his continuous service. These options expire on April 10, 2036. According to the disclosure, the economic benefit of this director compensation passes to Maverick Ventures Investment Fund, L.P. through a management fee offset, and Singer disclaims beneficial ownership except to the extent of his pecuniary interest.
Infleqtion, Inc. reported that director David B. Singer received a grant of stock options covering 33,928 shares of common stock at an exercise price of $12.59 per share. The options were awarded at no cost and expire on April 10, 2036.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to Mr. Singer’s continued board service. After this grant, 33,928 derivative securities of this type are reported as beneficially owned indirectly.
Infleqtion, Inc. reported that director David B. Singer received a grant of stock options covering 33,928 shares of common stock at an exercise price of $12.59 per share. The options were awarded at no cost and expire on April 10, 2036.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to Mr. Singer’s continued board service. After this grant, 33,928 derivative securities of this type are reported as beneficially owned indirectly.
Infleqtion, Inc. director David B. Singer received a grant of stock options covering 33,928 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036.
These options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to his continuous service under the company’s 2026 Equity Incentive Plan. Vesting may accelerate under the Non-Employee Director Compensation Policy.
Infleqtion, Inc. director David B. Singer received a grant of stock options covering 33,928 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036.
These options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to his continuous service under the company’s 2026 Equity Incentive Plan. Vesting may accelerate under the Non-Employee Director Compensation Policy.
Infleqtion, Inc. director Dawn Clawson Meyerriecks received a grant of stock options as equity compensation. She was awarded 33,928 options to buy Infleqtion common stock at an exercise price of $12.59 per share, expiring on April 10, 2036. Following this grant, she holds 33,928 derivative securities linked to common stock.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting after April 10, 2026, subject to her continued service under the company’s 2026 Equity Incentive Plan and any acceleration provisions in the Non-Employee Director Compensation Policy.
Infleqtion, Inc. director Dawn Clawson Meyerriecks received a grant of stock options as equity compensation. She was awarded 33,928 options to buy Infleqtion common stock at an exercise price of $12.59 per share, expiring on April 10, 2036. Following this grant, she holds 33,928 derivative securities linked to common stock.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting after April 10, 2026, subject to her continued service under the company’s 2026 Equity Incentive Plan and any acceleration provisions in the Non-Employee Director Compensation Policy.
Infleqtion, Inc. director Kristina M. Johnson received a grant of stock options covering 22,619 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036. After this grant, she holds 22,619 derivative securities of this type.
The options vest in full on the earlier of May 23, 2027 or the company’s next annual stockholders’ meeting following April 10, 2026, subject to her continuous service under Infleqtion’s 2026 Equity Incentive Plan and its Non-Employee Director Compensation Policy.
Infleqtion, Inc. director Kristina M. Johnson received a grant of stock options covering 22,619 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036. After this grant, she holds 22,619 derivative securities of this type.
The options vest in full on the earlier of May 23, 2027 or the company’s next annual stockholders’ meeting following April 10, 2026, subject to her continuous service under Infleqtion’s 2026 Equity Incentive Plan and its Non-Employee Director Compensation Policy.
Infleqtion, Inc. director James Eric Bjornholt received a grant of stock options covering 22,619 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036. They vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to his continuous service under the company’s 2026 Equity Incentive Plan.
Infleqtion, Inc. director James Eric Bjornholt received a grant of stock options covering 22,619 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036. They vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to his continuous service under the company’s 2026 Equity Incentive Plan.
Infleqtion, Inc. director Catherine P. Lego received a grant of stock options as part of her compensation. She was awarded 22,619 options to buy Infleqtion common stock at an exercise price of $12.59 per share, expiring on April 10, 2036.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, provided she maintains continuous service under the company’s 2026 Equity Incentive Plan. After this grant, she directly holds options for 22,619 shares.
Infleqtion, Inc. director Catherine P. Lego received a grant of stock options as part of her compensation. She was awarded 22,619 options to buy Infleqtion common stock at an exercise price of $12.59 per share, expiring on April 10, 2036.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, provided she maintains continuous service under the company’s 2026 Equity Incentive Plan. After this grant, she directly holds options for 22,619 shares.
Infleqtion, Inc. director James Eric Bjornholt reported receiving a grant of stock options covering 29,950 shares of Common Stock on February 13, 2026. The options have an exercise price of $13.22 per share and expire on February 12, 2036.
According to the filing, one-third of the underlying shares vest on December 21, 2026, with 1/36 of the total vesting each month thereafter, subject to his continued service. This amendment also corrects a prior scrivener’s error in the originally reported first exercisable date.
Infleqtion, Inc. director James Eric Bjornholt reported receiving a grant of stock options covering 29,950 shares of Common Stock on February 13, 2026. The options have an exercise price of $13.22 per share and expire on February 12, 2036.
According to the filing, one-third of the underlying shares vest on December 21, 2026, with 1/36 of the total vesting each month thereafter, subject to his continued service. This amendment also corrects a prior scrivener’s error in the originally reported first exercisable date.
Infleqtion, Inc. reported full-year 2025 results and issued 2026 revenue guidance of $40 million, reflecting what it describes as growing demand for its quantum sensing and computing solutions. For 2025, loss from operations was $35.3 million, improving from $53.0 million in 2024.
On a non-GAAP basis, Infleqtion reported a 2025 non-GAAP operating loss of $28.1 million and a non-GAAP net loss of $24.6 million, both narrower than 2024. Stock-based compensation totaled $3.1 million in 2025, down from $3.7 million in 2024. The company will discuss these results and its outlook on an April 8, 2026 conference call.
Infleqtion, Inc. reported full-year 2025 results and issued 2026 revenue guidance of $40 million, reflecting what it describes as growing demand for its quantum sensing and computing solutions. For 2025, loss from operations was $35.3 million, improving from $53.0 million in 2024.
On a non-GAAP basis, Infleqtion reported a 2025 non-GAAP operating loss of $28.1 million and a non-GAAP net loss of $24.6 million, both narrower than 2024. Stock-based compensation totaled $3.1 million in 2025, down from $3.7 million in 2024. The company will discuss these results and its outlook on an April 8, 2026 conference call.
Infleqtion, Inc. has filed an S-1 registering up to 10,425,000 shares of common stock issuable upon exercise of existing warrants, plus up to 121,829,432 outstanding shares and 75,000 private warrants for resale by current holders. Infleqtion will receive cash only if warrant holders exercise their warrants; it receives no proceeds from the resale of shares or warrants.
The company recently completed a SPAC Business Combination with Churchill Capital Corp X, raised approximately $126.5 million through a PIPE financing for 12,654,760 shares, and now trades on the NYSE under “INFQ” and “INFQ WS.” It develops quantum sensing, computing and software solutions and reported net losses of $31.8 million in 2025 and $53.8 million in 2024, with an accumulated deficit of $231.1 million. Infleqtion highlights significant technology, execution, government-dependency and cybersecurity risks as it scales its emerging quantum platform.
Infleqtion, Inc. has filed an S-1 registering up to 10,425,000 shares of common stock issuable upon exercise of existing warrants, plus up to 121,829,432 outstanding shares and 75,000 private warrants for resale by current holders. Infleqtion will receive cash only if warrant holders exercise their warrants; it receives no proceeds from the resale of shares or warrants.
The company recently completed a SPAC Business Combination with Churchill Capital Corp X, raised approximately $126.5 million through a PIPE financing for 12,654,760 shares, and now trades on the NYSE under “INFQ” and “INFQ WS.” It develops quantum sensing, computing and software solutions and reported net losses of $31.8 million in 2025 and $53.8 million in 2024, with an accumulated deficit of $231.1 million. Infleqtion highlights significant technology, execution, government-dependency and cybersecurity risks as it scales its emerging quantum platform.